vs
美泰（MAT）与Insulet Corporation（PODD）财务数据对比。点击上方公司名可切换其他公司
美泰的季度营收约是Insulet Corporation的1.1倍（$862.2M vs $783.7M），Insulet Corporation净利率更高（13.0% vs 7.1%，领先5.9%），Insulet Corporation同比增速更快（31.2% vs 4.3%），Insulet Corporation自由现金流更多（$48.2M vs $-88.1M），过去两年Insulet Corporation的营收复合增速更高（33.2% vs -10.6%）
美泰是美国知名玩具及娱乐企业，旗下影视制作部门美泰影业运营时间为2018年9月6日至2025年6月2日。其前身为2013年10月16日成立的美泰Playground Productions，更早可追溯至美泰娱乐、美泰工作室等集团原有娱乐业务品牌。
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
MAT vs PODD — 直观对比
营收规模更大
MAT
是对方的1.1倍
$783.7M
营收增速更快
PODD
高出26.9%
4.3%
净利率更高
PODD
高出5.9%
7.1%
自由现金流更多
PODD
多$136.3M
$-88.1M
两年增速更快
PODD
近两年复合增速
-10.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $862.2M | $783.7M |
| 净利润 | $61.0M | $101.6M |
| 毛利率 | 44.9% | 72.6% |
| 营业利润率 | — | 18.7% |
| 净利率 | 7.1% | 13.0% |
| 营收同比 | 4.3% | 31.2% |
| 净利润同比 | 251.4% | 0.9% |
| 每股收益（稀释后） | $0.20 | $1.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATPODD
| Q1 26 | $862.2M | — | ||
| Q4 25 | $1.8B | $783.7M | ||
| Q3 25 | $1.7B | $706.3M | ||
| Q2 25 | $1.0B | $649.1M | ||
| Q1 25 | $826.6M | $569.0M | ||
| Q4 24 | $1.6B | $597.5M | ||
| Q3 24 | $1.8B | $543.9M | ||
| Q2 24 | $1.1B | $488.5M |
净利润MATPODD
| Q1 26 | $61.0M | — | ||
| Q4 25 | $106.2M | $101.6M | ||
| Q3 25 | $278.4M | $87.6M | ||
| Q2 25 | $53.4M | $22.5M | ||
| Q1 25 | $-40.3M | $35.4M | ||
| Q4 24 | $140.9M | $100.7M | ||
| Q3 24 | $372.4M | $77.5M | ||
| Q2 24 | $56.9M | $188.6M |
毛利率MATPODD
| Q1 26 | 44.9% | — | ||
| Q4 25 | 45.9% | 72.6% | ||
| Q3 25 | 50.0% | 72.2% | ||
| Q2 25 | 50.9% | 69.7% | ||
| Q1 25 | 49.4% | 71.9% | ||
| Q4 24 | 50.7% | 72.1% | ||
| Q3 24 | 53.1% | 69.3% | ||
| Q2 24 | 49.2% | 67.7% |
营业利润率MATPODD
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | 18.7% | ||
| Q3 25 | 21.9% | 16.7% | ||
| Q2 25 | 7.7% | 18.7% | ||
| Q1 25 | -6.4% | 15.6% | ||
| Q4 24 | 9.6% | 18.3% | ||
| Q3 24 | 26.5% | 16.2% | ||
| Q2 24 | 7.7% | 11.2% |
净利率MATPODD
| Q1 26 | 7.1% | — | ||
| Q4 25 | 6.0% | 13.0% | ||
| Q3 25 | 16.0% | 12.4% | ||
| Q2 25 | 5.2% | 3.5% | ||
| Q1 25 | -4.9% | 6.2% | ||
| Q4 24 | 8.6% | 16.9% | ||
| Q3 24 | 20.2% | 14.2% | ||
| Q2 24 | 5.3% | 38.6% |
每股收益（稀释后）MATPODD
| Q1 26 | $0.20 | — | ||
| Q4 25 | $0.32 | $1.42 | ||
| Q3 25 | $0.88 | $1.24 | ||
| Q2 25 | $0.16 | $0.32 | ||
| Q1 25 | $-0.12 | $0.50 | ||
| Q4 24 | $0.40 | $1.38 | ||
| Q3 24 | $1.09 | $1.08 | ||
| Q2 24 | $0.17 | $2.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $866.0M | — |
| 总债务越低越好 | $2.3B | $930.8M |
| 股东权益账面价值 | $2.1B | $1.5B |
| 总资产 | $6.3B | $3.2B |
| 负债/权益比越低杠杆越低 | 1.11× | 0.61× |
8季度趋势，按日历期对齐
现金及短期投资MATPODD
| Q1 26 | $866.0M | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $691.9M | — | ||
| Q2 25 | $870.5M | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $723.5M | — | ||
| Q2 24 | $722.4M | — |
总债务MATPODD
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $930.8M | ||
| Q3 25 | $2.3B | $934.9M | ||
| Q2 25 | $2.3B | $939.0M | ||
| Q1 25 | $2.3B | $1.6B | ||
| Q4 24 | $2.3B | $1.3B | ||
| Q3 24 | $2.3B | $1.4B | ||
| Q2 24 | $2.3B | $1.4B |
股东权益MATPODD
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.3B | $1.4B | ||
| Q2 25 | $2.2B | $1.5B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.3B | $1.2B | ||
| Q3 24 | $2.3B | $1.1B | ||
| Q2 24 | $2.0B | $998.4M |
总资产MATPODD
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.6B | $3.2B | ||
| Q3 25 | $6.6B | $3.0B | ||
| Q2 25 | $6.2B | $3.5B | ||
| Q1 25 | $6.2B | $3.5B | ||
| Q4 24 | $6.5B | $3.1B | ||
| Q3 24 | $6.5B | $3.0B | ||
| Q2 24 | $5.9B | $2.9B |
负债/权益比MATPODD
| Q1 26 | 1.11× | — | ||
| Q4 25 | 1.04× | 0.61× | ||
| Q3 25 | 1.03× | 0.68× | ||
| Q2 25 | 1.08× | 0.64× | ||
| Q1 25 | 1.10× | 1.21× | ||
| Q4 24 | 1.03× | 1.07× | ||
| Q3 24 | 1.01× | 1.21× | ||
| Q2 24 | 1.18× | 1.36× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $183.3M |
| 自由现金流经营现金流 - 资本支出 | $-88.1M | $48.2M |
| 自由现金流率自由现金流/营收 | -10.2% | 6.2% |
| 资本支出强度资本支出/营收 | 7.6% | 17.2% |
| 现金转化率经营现金流/净利润 | — | 1.80× |
| 过去12个月自由现金流最近4个季度 | — | $377.7M |
8季度趋势，按日历期对齐
经营现金流MATPODD
| Q1 26 | — | — | ||
| Q4 25 | $796.6M | $183.3M | ||
| Q3 25 | $72.0M | $125.7M | ||
| Q2 25 | $-300.1M | $196.5M | ||
| Q1 25 | $24.8M | $63.8M | ||
| Q4 24 | $862.1M | $147.7M | ||
| Q3 24 | $155.8M | $98.5M | ||
| Q2 24 | $-252.9M | $96.5M |
自由现金流MATPODD
| Q1 26 | $-88.1M | — | ||
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M |
自由现金流率MATPODD
| Q1 26 | -10.2% | — | ||
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% |
资本支出强度MATPODD
| Q1 26 | 7.6% | — | ||
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% |
现金转化率MATPODD
| Q1 26 | — | — | ||
| Q4 25 | 7.50× | 1.80× | ||
| Q3 25 | 0.26× | 1.43× | ||
| Q2 25 | -5.62× | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | 6.12× | 1.47× | ||
| Q3 24 | 0.42× | 1.27× | ||
| Q2 24 | -4.45× | 0.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MAT
暂无分部数据
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
